Notably, GLP-1 RAs also tend to promote growth of genera known for supporting gut barrier integrity (such as Akkermansia ), further hinting at a positive remodeling of the gut ecosystem (34, 35)
[DOI] [PubMed] [Google Scholar] 95.La China S., Zanichelli G., De Vero L., Gullo M
Cardiovascular outcomes trials such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown that certain GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
A head-to-head comparison of oral and injectable GLP-1 drugs for obesity, including oral semaglutide, orforglipron, aleniglipron, and VK2735 versus their injectable counterparts